SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
AstraZeneca Posts Good Q3
October 19, 2005
 · 
1 min read
AstraZeneca’s Crestor May Harm Kidneys, Group Says
October 19, 2005
 · 
1 min read
Seroquel: The Patient’s Choice
October 19, 2005
 · 
1 min read
Policy
FDA: Use Caution When Prescribing Crestor
October 19, 2005
 · 
1 min read
Attacking Heart Attacks
October 19, 2005
 · 
1 min read
Policy
Florida Fails To Renew Drug Company Program
October 19, 2005
 · 
1 min read
Drug Development
Drug Firms Pledge More Cash For Animal Research
October 19, 2005
 · 
1 min read
Policy
Allergy, Asthma Drug Labels OK For Kids
October 19, 2005
 · 
1 min read
AstraZeneca Cautions Doctors On High Dose Crestor
October 19, 2005
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
May 1, 2026
 · 
15 min read
Press Releases
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
April 29, 2026
 · 
3 min read
Press Releases
AstraZeneca results: Q1 2026
April 29, 2026
 · 
8 min read
Press Releases
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
April 28, 2026
 · 
12 min read
Press Releases
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
April 27, 2026
 · 
16 min read
Press Releases
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
April 20, 2026
 · 
6 min read
Press Releases
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
April 20, 2026
 · 
10 min read
Press Releases
Saphnelo® subcutaneous approved in Canada for the treatment of systemic lupus erythematosus
April 14, 2026
 · 
9 min read
Press Releases
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
April 2, 2026
 · 
19 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
March 9, 2026
 · 
19 min read
Load More